AstraZeneca’s Danicopan Shows Positive Results in Phase III Trial
Danicopan, an oral Factor D inhibitor developed by AstraZeneca, was expected to fail a phase II trial in rare kidney disease in 2020, but a new readout could revive the drug. Danicopan (ALXN2040) has demonstrated efficacy as an adjunct treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) who have extravascular hemolysis (EVH) - the breakdown of red blood cells in the spleen, bone marrow, or liver. The drug is being developed for use in PNH in combination with Alexion's established C5 inhibitor therapies Soliris (eculizumab) and Ultomiris (ravulizumab), as well as for eye disease geog...
